Specify a stock or a cryptocurrency in the search bar to get a summary
Pharvaris BV
9ENPharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands. Address: Emmy Noetherweg 2, Leiden, Netherlands, 2333 BK
Analytics
WallStreet Target Price
34.59 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 9EN
Dividend Analytics 9EN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 9EN
Stock Valuation 9EN
Financials 9EN
Results | 2019 | Dynamics |